De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017Giuseppe Curigliano, Andrew Tutt, Beat Thürlimann et al.|Annals of Oncology|2017Cited by 1.3k
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trialAleix Prat, Joaquín Gavilá, Cristina Saura et al.|The Lancet Oncology|2019Cited by 199
The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancerCarlos A. Castañeda, Eva Ciruelos, H. Cortés-Funes et al.|Cancer and Metastasis Reviews|2010Cited by 171
Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast CancerJosé Baselga, Frederico Costa, J. G. M. Segalla et al.|Journal of Clinical Oncology|2012Cited by 163
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluationAleix Prat, PierFranco Conte, Valentina Guarneri et al.|The Lancet Oncology|2020Cited by 75